Literature DB >> 11901151

Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.

Kotha Subbaramaiah1, Larry Norton, William Gerald, Andrew J Dannenberg.   

Abstract

Markedly increased levels of cyclooxygenase-2 (COX-2) mRNA, protein, and prostaglandin E(2) synthesis were detected in HER-2/neu-transformed human mammary epithelial cells (184B5/HER) compared with its nontransformed partner cell line (184B5). HER-2/neu stimulated COX-2 transcription via the Ras --> Raf --> MAPK pathway. The inductive effects of HER-2/neu were mediated, in part, by enhanced binding of AP-1 (c-Jun, c-Fos, and ATF-2) to the cyclic AMP-response element (-59/-53) of the COX-2 promoter. The potential contribution of the transcription factor PEA3 was also investigated. Elevated levels of PEA3 were detected in 184B5/HER cells. A PEA3 site (-75/-72) was identified juxtaposed to the cyclic AMP-response element. HER-2/neu-mediated activation of the COX-2 promoter was blocked by mutagenizing the PEA3 site or overexpressing antisense to PEA3. To determine whether HER-2/neu status was also a determinant of COX-2 expression in vivo, we compared levels of COX-2 protein in HER-2/neu-positive and -negative human breast cancers. Increased amounts of COX-2 were detected in HER-2/neu-positive tumors. Taken together, these results suggest that closely spaced PEA3 and cyclic AMP-response elements are required for HER-2/neu-mediated induction of COX-2 transcription. The clear relationship between HER-2/neu status and COX-2 expression in human breast tumors suggests that this mechanism is likely to be operative in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901151     DOI: 10.1074/jbc.M111415200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  90 in total

1.  The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.

Authors:  Shiuan Chen; Jingjing Ye; Ikuko Kijima; Dean Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype.

Authors:  Theodore M Brasky; Matthew R Bonner; Kirsten B Moysich; Christine B Ambrosone; Jing Nie; Meng Hua Tao; Stephen B Edge; Bhaskar V S Kallakury; Catalin Marian; David S Goerlitz; Maurizio Trevisan; Peter G Shields; Jo L Freudenheim
Journal:  Cancer Causes Control       Date:  2011-04-23       Impact factor: 2.506

3.  Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-05       Impact factor: 11.205

Review 4.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

5.  Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines.

Authors:  Claudia Bocca; Francesca Bozzo; Andrea Bassignana; Antonella Miglietta
Journal:  Mol Cell Biochem       Date:  2010-12-08       Impact factor: 3.396

6.  The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3.

Authors:  Baoqiang Guo; Rosemary E Sallis; Amanda Greenall; Marleen M R Petit; Erik Jansen; Leonie Young; Wim J M Van de Ven; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

Authors:  Anthony Lucci; Savitri Krishnamurthy; Balraj Singh; Isabelle Bedrosian; Funda Meric-Bernstam; James Reuben; Kristine Broglio; Kailash Mosalpuria; Ashutosh Lodhi; Laura Vincent; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2008-07-29       Impact factor: 4.872

9.  Expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathological prognostic factors.

Authors:  Eunmi Nam; Soon Nam Lee; Seock-Ah Im; Do-Yeun Kim; Kyoung Eun Lee; Sun Hee Sung
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

10.  Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Authors:  Anne-Sophie Hamy; Sandrine Tury; Xiaofei Wang; Junheng Gao; Jean-Yves Pierga; Sylvie Giacchetti; Etienne Brain; Barbara Pistilli; Michel Marty; Marc Espié; Gabriel Benchimol; Enora Laas; Marick Laé; Bernard Asselain; Brice Aouchiche; Martin Edelman; Fabien Reyal
Journal:  J Clin Oncol       Date:  2019-01-31       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.